SCHEMBL6728486

SCHEMBL6728486

NCc1cccc(-c2cnc(C(=O)N3CCN(S(=O)(=O)c4nc5ccc(Cl)cc5[nH]4)CC3)nc2)[n+]1[O-]

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
F10 P00742 6/20 0.40
HRH4 Q9H3N8 5/20 0.39
HRH3 Q9Y5N1 1/20 0.39
KMT2A Q03164 4/20 0.37
MAPT P10636 3/20 0.37
MEN1 O00255 2/20 0.37
GAA P10253 1/20 0.36
ALOX15 P16050 1/20 0.36
LMNA P02545 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 2/20 0.36
POLB P06746 1/20 0.36
PKM P14618 1/20 0.36
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6728471 0.94 GAA (0.36) F10KMT2AGAALMNAALDH1A1
SCHEMBL6730948 0.93 HRH4 (0.39) F10HRH4HRH3KMT2AMAPT
SCHEMBL6731713 0.90 HRH4 (0.41) F10HRH4HRH3KMT2AMAPT
SCHEMBL6731166 0.90 F10 (0.44) F10HRH4HRH3KMT2AMAPT
SCHEMBL6725174 0.89 F10 (0.40) F10HRH4HRH3KMT2AMAPT
SCHEMBL6726101 0.88 HRH4 (0.42) F10HRH4HRH3KMT2AMAPT
SCHEMBL6730953 0.87 GAA (0.37) F10KMT2AGAALMNAALDH1A1
SCHEMBL6729096 0.87 HRH4 (0.42) F10HRH4HRH3KMT2AMAPT
SCHEMBL6729012 0.85 F10 (0.51) F10
SCHEMBL6728582 0.84 F10 (0.40) F10HRH4HRH3KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction F2, CYC1, SULT2A1 F10 19/4885HRH4 506/4885HRH3 1035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.